VCTs attracted 'stellar amounts' of capital in the 2017/18 tax year and, says Ian Battersby, it will be interesting to see how quickly - and well - this gets deployed now a new chapter for the tax-efficient sector has begun
As the curtain falls on another tax year, there is every reason to think the tax-advantaged investment community will have digested the general outcome of the Patient Capital Review (PCR) - that is, the changes announced in the November Budget and subsequent update in the Spring Statement. Bar a handful of minor adjustments, future tax relief will now only be available to those investors prepared to take risk in providing capital aimed at helping younger companies to grow. Many established venture capital trust (VCT) providers came to market early in 2017/18 and closed with stellar am...
To continue reading this article...
Join Professional Adviser for free
Signup and gain exclusive members-only insights
- Unlimited access to real-time news, industry insights and market intelligence
- Stay ahead of the curve with spotlights on emerging trends and technologies
- Receive breaking news stories straight to your inbox in the daily newsletters
- Make smart business decisions with the latest developments in regulation, investing retirement and protection
- Members-only access to the editor’s weekly Friday commentary
- Be the first to hear about our events and awards programmes
